older adult subjects commencing in the fourth quarter of 2008. The
intent of this head-to-head trial is to evaluate the immunogenicity of
the seasonal influenza VLP vaccine candidate as compared with that of
an approved, marketed vaccine in the older adult population.
-- Continued to advance two additional new vaccine discovery programs, one
for Varicella Zoster (Shingles) and a second for an undisclosed disease
target with the goal of progressing both of these candidates through
proof of concept animal studies during the next two quarters.
-- Enhanced VLP technology capabilities by developing a new approach in
creating VLPs that expands our ability to apply VLPs to a broader
number of potential vaccine disease targets.
-- Announced the completion of construction for our GMP pilot plant in the
Company's Rockville, Maryland headquarters with a ribbon cutting
ceremony held on May 1, 2008. This facility will showcase the
capability of our ready to use and disposable production technology in
a relatively low cost environment.
-- Progressed the collaboration with GE Healthcare to develop and market a
pandemic influenza vaccine manufacturing solution for selected
-- Completed the sale of assets related to Estrasorb in the United States,
Canada and Mexico to Graceway Pharmaceuticals, LLC ("Graceway") in
February 2008. As part of that sale, Novavax entered into a supply
agreement with Graceway which requires the Company to manufacture
additional units of Estrasorb, with final delivery expected in mid-
"We continue to make solid progress in our clinical development
programs and currently are on track to achieve our plans for 2008," said
Novavax Chief Executive Officer Dr. Rahul Singhvi. "By th
|SOURCE Novavax, Inc.|
Copyright©2008 PR Newswire.
All rights reserved